C4 Therapeutics Inc.

06/24/2026 | Press release | Distributed by Public on 06/24/2026 14:22

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 24, 2026, C4 Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders considered and voted on the four proposals set forth below, each of which is described in greater detail in the Company's definitive proxy statement on Schedule 14A, which was filed with the U.S. Securities and Exchange Commission on April 29, 2026. The final voting results are set forth below.
a) The stockholders of the Company elected each of Andrew J. Hirsch, Stephen Fawell, Ph.D., and Utpal Koppikar as Class III directors, to hold office until the 2029 annual meeting of stockholders and until their respective successors have been duly elected and qualified or until his earlier resignation or removal. The results of the stockholders' vote with respect to the election of the Class III directors were as follows:
For
Withheld
Broker Non-Votes
Andrew J. Hirsch
47,797,964
8,247,406
21,049,125
Stephen Fawell, Ph.D.
47,811,414
8,233,956
21,049,125
Utpal Koppikar
46,491,892
9,553,478
21,049,125
b) The stockholders of the Company cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers. The results of the stockholders' vote with respect to this proposal were as follows:
For
Against
Abstain
Broker Non-Votes
54,935,574
1,070,926
38,870
21,049,125
c) The stockholders of the Company ratified the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders' vote with respect to this ratification proposal were as follows:
For
Against
Abstain
Broker Non-Votes
76,891,210
185,427
17,858
0
d) The Company's stockholders approved an amendment to the Company's 2020 Stock Option and Incentive Plan to amend the evergreen provision to include any outstanding pre-funded warrants in the total number of shares of common stock that are issued and outstanding as of each December 31 for purposes of calculating the evergreen increase. The results of the stockholders' vote with respect to this proposal were as follows:
For
Against
Abstain
Broker Non-Votes
33,713,572
22,287,787
44,011
21,049,125
No other matters were submitted to or voted on by the Company's stockholders at the Annual Meeting.
C4 Therapeutics Inc. published this content on June 24, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 24, 2026 at 20:22 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]